See KIT2014 in action! KIT2014 is a cell-permeable cAMP modulating peptide that disrupts the interaction of PI3Kgamma with its partner proteins, leading to enhanced cAMP responses within the cell. Localized cAMP elevation potentiates the opening of cystic fibrosis transmembrane conductance regulator (CFTR) protein channels at the plasma membrane, directly impacting mucus hypersecretion, airway inflammation and bronchoconstriction, issues that are inherent to cystic fibrosis (CF). In CF patients, treatment with KIT2014 is believed to restore the function of CFTR mutants by potentiating the effects of CFTR modulators (Ghigo et al., Science Translational Medicine 2022).